Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 17, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in Ordinary Share ADRs.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is the acquisition of a beneficial interest in Ordinary Share ADRs by Mrs. P. Phelan. This transaction arose from the reinvestment of the dividend paid to Ordinary Share ADR holders on October 6, 2005, through the US Global BuyDirect Plan administered by The Bank of New York.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Type: Reinvestment of dividend via US Global BuyDirect Plan.
- Individual Involved: Mrs. P. Phelan.
- Shares Acquired: 0.2079 Ordinary Share ADRs.
- Price per ADR: $51.7636.
- Dividend Date: October 6, 2005.
- Notification Date: October 17, 2005.